Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.9.3735

Insulin-like Growth Factor-1, IGF-binding Protein-3, C-peptide and Colorectal Cancer: a Case-control Study  

Joshi, Pankaj (Department of Preventive Medicine, Kangwon National University School of Medicine)
Joshi, Rakhi Kumari (Department of Preventive Medicine, Kangwon National University School of Medicine)
Kim, Woo Jin (Department of Internal Medicine, Kangwon National University School of Medicine)
Lee, Sang-Ah (Department of Preventive Medicine, Kangwon National University School of Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.9, 2015 , pp. 3735-3740 More about this Journal
Abstract
Context: Insulin-like growth factor peptides play important roles in regulating cell growth, cell differentiation, and apoptosis, and have been demonstrated to promote the development of colorectal cancer (CRC). Objective: To examine the association of insulin-related biomarkers including insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3) and C-peptide with CRC risk and assess their relevance in predictive models. Materials and Methods: The odds ratios of colorectal cancer for serum levels of IGF-1, IGFBP-3 and C-peptide were estimated using unconditional logistic regression models in 100 colorectal cancer cases and 100 control subjects. Areas under the receiving curve (AUC) and integrated discrimination improvement (IDI) statistics were used to assess the discriminatory potential of the models. Results: Serum levels of IGF-1 and IGFBP-3 were negatively associated with colorectal cancer risk (OR=0.07, 95%CI: 0.03-0.16, P for trend <.01, OR=0.06, 95%CI: 0.03-0.15, P for trend <.01 respectively) and serum C-peptide was positively associated with risk of colorectal cancer (OR=4.38, 95%CI: 2.13-9.06, P for trend <.01). Compared to the risk model, prediction for the risk of colorectal cancer had substantially improved when all selected biomarkers IGF-1, IGFBP-3 and inverse value of C-peptide were simultaneously included inthe reference model [P for AUC improvement was 0.02 and the combined IDI reached 0.166% (95 % CI; 0.114-0.219)]. Conclusions: The results provide evidence for an association of insulin-related biomarkers with colorectal cancer risk and point to consideration as candidate predictor markers.
Keywords
Colorectal cancer; insulin-related biomarkers (IGF-1, IGFBP-3, C-peptide); case-control study;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Davies M, Gupta S, Goldspink G, et al (2006). The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence. Int J Colorectal Dis, 21, 201-8.   DOI
2 DeLong ER, DeLong DM, Clarke-Pearson DL (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics, 44, 837-45.   DOI
3 Durai R, Yang W, Gupta S, et al (2005). The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis, 20, 203-20.   DOI
4 Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.   DOI
5 Ferry RJ, Jr., Cerri RW, Cohen P (1999). Insulin-like growth factor binding proteins: new proteins, new functions. Horm Res, 51, 53-67.   DOI
6 Firth SM, Baxter RC (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev, 23, 824-54.   DOI
7 Giovannucci E (2001). Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr, 131, 3109-20.
8 Giovannucci E, Pollak MN, Platz EA, et al (2000). A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev, 9, 345-9.
9 Gunter MJ, Hoover DR, Yu H, et al (2008). Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res, 68, 329-37.   DOI
10 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
11 Jenab M, Riboli E, Cleveland RJ, et al (2007). Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer, 121, 368-76.   DOI
12 Joshi RK, Lee SA (2014). Obesity related adipokines and colorectal cancer: a review and meta-analysis. Asian Pac J Cancer Prev, 15, 397-405.   DOI   ScienceOn
13 Kaaks R (2004). Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp, 262, 247-60.
14 Kaaks R, Toniolo P, Akhmedkhanov A, et al (2000). Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst, 92, 1592-600.   DOI
15 Ma J, Pollak MN, Giovannucci E, et al (1999). Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst, 91, 620-5.   DOI
16 Kabat GC, Kim MY, Strickler HD, et al (2012). A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women. Br J Cancer, 106, 227-32.   DOI
17 Khandwala HM, McCutcheon IE, Flyvbjerg A, et al (2000). The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev, 21, 215-44.   DOI
18 Ma J, Giovannucci E, Pollak M, et al (2004). A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst, 96, 546-53.   DOI
19 Nomura AM, Stemmermann GN, Lee J, et al (2003). Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. Am J Epidemiol, 158, 424-31.   DOI
20 Ollberding NJ, Cheng I, Wilkens LR, et al (2012). Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the risk of colorectal cancer: the Multiethnic Cohort study. Cancer Epidemiol Biomarkers Prev, 21, 810-20.   DOI
21 Otani T, Iwasaki M, Sasazuki S, et al (2007). Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer, 120, 2007-12.   DOI
22 Palmqvist R, Hallmans G, Rinaldi S, et al (2002). Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut, 50, 642-6.   DOI
23 Probst-Hensch NM, Yuan JM, Stanczyk FZ, et al (2001). IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer, 85, 1695-9.   DOI
24 Palmqvist R, Stattin P, Rinaldi S, et al (2003). Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: a prospective study in northern Sweden. Int J Cancer, 107, 89-93.   DOI
25 Pollak M (2000). Insulin-like growth factor physiology and cancer risk. Eur J Cancer, 36, 1224-8.   DOI
26 Pollak M (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 8, 915-28.   DOI
27 Renehan AG, Zwahlen M, Minder C, et al (2004). Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet, 363, 1346-53.   DOI
28 Rinaldi S, Cleveland R, Norat T, et al (2010). Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer, 126, 1702-15.
29 Sandhu MS, Dunger DB, Giovannucci EL (2002). Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst, 94, 972-80.   DOI
30 Schoen RE, Tangen CM, Kuller LH, et al (1999). Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst, 91, 1147-54.   DOI
31 Tran TT, Naigamwalla D, Oprescu AI, et al (2006). Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology, 147, 1830-7.   DOI
32 Wei EK, Ma J, Pollak MN, et al (2005). A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev, 14, 850-5.   DOI